SCHEMBL3033101

SCHEMBL3033101

CCc1ccc(CNC(=O)c2[nH]cnc2Cl)c(F)c1Oc1cc(Cl)cc(C#N)c1

nearest known ligand 0.45

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.45
KCNH2 Q12809 3/20 0.41
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
DDR1 Q08345 4/20 0.34
EPHX2 P34913 1/20 0.33
SLC22A12 Q96S37 1/20 0.33
LMNA P02545 1/20 0.33
KLKB1 P03952 2/20 0.32
ROCK2 O75116 1/20 0.32
ROCK1 Q13464 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
RORC P51449 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3023587 0.92 CYP3A4 (0.49) CYP3A4KCNH2CYP2C9CYP2C19DDR1
SCHEMBL13560584 0.91 CYP3A4 (0.42) CYP3A4KCNH2CYP2C9CYP2C19DDR1
SCHEMBL3034302 0.89 CYP3A4 (0.41) CYP3A4KCNH2CYP2C9CYP2C19EPHX2
SCHEMBL3034271 0.88 CYP3A4 (0.41) CYP3A4KCNH2CYP2C9CYP2C19DDR1
SCHEMBL3035905 0.88 CYP3A4 (0.45) CYP3A4CYP2C9CYP2C19EPHX2LMNA
SCHEMBL3036047 0.88 CYP3A4 (0.43) CYP3A4KCNH2CYP2C9CYP2C19EPHX2
SCHEMBL13982245 0.87 LMNA (0.34) DDR1EPHX2LMNAKLKB1ROCK2
SCHEMBL13560513 0.86 CYP3A4 (0.44) CYP3A4CYP2C9CYP2C19EPHX2LMNA
SCHEMBL3027526 0.86 CYP3A4 (0.46) CYP3A4KCNH2CYP2C9CYP2C19DDR1
SCHEMBL3028060 0.86 CYP3A4 (0.46) CYP3A4KCNH2CYP2C9CYP2C19EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8304419-B2 Chemical compounds GLAXOSMITHKLINE LLC (US) 2012-11-06 US claimed
US-20100216746-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC (US) 2010-08-26 US claimed
US-8304419-B2 Chemical compounds GLAXOSMITHKLINE LLC (US) 2012-11-06 US disclosed
US-8304419-B2 Chemical compounds GLAXOSMITHKLINE LLC (US) 2012-11-06 US disclosed
US-8304419-B2 Chemical compounds GLAXOSMITHKLINE LLC (US) 2012-11-06 US disclosed
US-20100216746-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC (US) 2010-08-26 US disclosed
US-20100216746-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC (US) 2010-08-26 US disclosed
US-20100216746-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC (US) 2010-08-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216746-A1 CHEMICAL COMPOUNDS SAMHD1, POLRMT, NUDT1 CYP3A4 169/4885KCNH2 4114/4885CYP2C9 720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.